{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:23:20Z","timestamp":1768037000882,"version":"3.49.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific","doi-asserted-by":"publisher","award":["\u00a0"],"award-info":[{"award-number":["\u00a0"]}],"id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009750","name":"University of Rochester Medical Center, Rochester, NY","doi-asserted-by":"publisher","award":["\u00a0"],"award-info":[{"award-number":["\u00a0"]}],"id":[{"id":"10.13039\/100009750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The implantable cardioverter defibrillator (ICD) is effective for the prevention of sudden cardiac death (SCD) in patients with heart failure and a reduced ejection fraction (HFrEF). The benefit of the ICD in patients with advanced CKD, remains elusive. Moreover, the benefit of the ICD in patients with advanced chronic kidney disease (CKD) and HFrEF who are cardiac resynchronization therapy (CRT) recipients may be attenuated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Hypothesis<\/jats:title><jats:p>We hypothesized that patients with CKD who are CRT recipients may derive less benefit from the ICD due to the competing risk of dying prior to experiencing an arrhythmia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study population included 1,015 patients receiving CRT with defibrillator (CRT-D) device for primary prevention of SCD who were enrolled in either (Multicenter Automated Defibrillator Implantation Trial) MADIT-CRT trial or the Ranolazine in High-Risk Patients with Implanted Cardioverter Defibrillator (RAID) trial. The cohort was divided into two groups based on the stage of CKD: those with Stage 1 to 3a KD, labeled as (S1-S3a)KD. The second group included patients with Stage 3b to stage 5 kidney disease, labeled as (S3b-S5)KD. The primary endpoint was any ventricular tachycardia (VT) or ventricular fibrillation (VF) (Any VT\/VF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The cumulative incidence of Any VT\/VF was 23.5% in patients with (S1-S3a)KD and 12.6% in those with (S3b-S5)KD (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001) The incidence of Death without Any VT\/VF was 6.6% in patients with (S1-S3a)KD and 21.6% in patients with (S3b-S5)KD (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). A Fine and Gray multivariate competing risk regression model showed that Patients with (S3b-S5)KD had a 43% less risk of experiencing Any VT\/VF when compared to those with (S1-S3a)KD (HR\u2009=\u20090.56, 95% CI [0.33\u20130.94] <jats:italic>p<\/jats:italic>\u2009=\u20090.03. After two years of follow up, there was almost a 5-fold increased risk of Death without Any VT\/VF among patients with (S3b-S5)KD when compared to those with (S1-S3a)KD [HR\u2009=\u20094.63, 95% CI (2.46\u20138.72), <jats:italic>p<\/jats:italic> for interaction with time\u2009=\u20090.012].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Due to their lower incidence of arrhythmias and higher risk of dying prior to experiencing an arrhythmia, the benefit of the ICD may be attenuated in CRT recipients with advanced CKD. Future prospective trials should evaluate whether CRT without a defibrillator may be more appropriate for these patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1237118","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T19:23:55Z","timestamp":1692818635000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Primary prevention implantable cardioverter defibrillator in cardiac resynchronization therapy recipients with advanced chronic kidney disease"],"prefix":"10.3389","volume":"10","author":[{"given":"Ido","family":"Goldenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Kutyifa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Zareba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Tsu-Chau","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spencer Z.","family":"Rosero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arwa","family":"Younis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Schuger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"McNitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bronislava","family":"Polonsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilan","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet K.","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1056\/NEJMoa1211107","article-title":"Reduction in inappropriate therapy and mortality through ICD programming","volume":"367","author":"Moss","year":"2012","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1093\/eurheartj\/ehaa1057","article-title":"Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score","volume":"42","author":"Younis","year":"2021","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.ajkd.2014.04.007","article-title":"Do implantable defibrillators help patients with CKD?","volume":"64","author":"Charytan","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/europace\/euy305","article-title":"Risk of death without appropriate defibrillator shock in patients with advanced renal dysfunction","volume":"21","author":"Goldenberg","year":"2019","journal-title":"Europace"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1093\/europace\/euaa146","article-title":"Competing risk analysis of ventricular arrhythmia events in heart failure patients with moderately compromised renal dysfunction","volume":"22","author":"Goldenberg","year":"2020","journal-title":"Europace"},{"key":"B7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/CIRCEP.114.002109","article-title":"Defibrillator therapy in chronic kidney disease: is it worth it?","volume":"7","author":"Patton","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.cpcardiol.2020.100639","article-title":"Implantable cardioverter defibrillators and chronic kidney disease","volume":"46","author":"Kiage","year":"2021","journal-title":"Curr Probl Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jacc.2018.04.086","article-title":"Ranolazine in high-risk patients with implanted cardioverter-defibrillators: the RAID trial","volume":"72","author":"Zareba","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B11","volume-title":"Harrison\u2019s principles of internal medicine","author":"Jameson","year":"2018"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.19102\/icrm.2020.110803","article-title":"Efficacy of implantable cardioverter-defibrillators for secondary prevention of sudden cardiac death in patients with End-stage renal disease","volume":"11","author":"Payne","year":"2020","journal-title":"J Innov Card Rhythm Manag"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1161\/CIRCULATIONAHA.119.039818","article-title":"Prophylactic use of implantable cardioverter-defibrillators in the prevention of sudden cardiac death in dialysis patients","volume":"139","author":"Jukema","year":"2019","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/j.ajkd.2013.12.009","article-title":"Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials","volume":"64","author":"Pun","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.5935\/0101-2800.20170033","article-title":"Ventricular arrhythmia in chronic kidney disease patients","volume":"39","author":"Bonato","year":"2017","journal-title":"J Bras Nefrol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1161\/CIR.0000000000000548","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines and the heart rhythm society","volume":"138","author":"Al-Khatib","year":"2018","journal-title":"Circulation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"Kober","year":"2016","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-Resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"630399","DOI":"10.3389\/fcvm.2021.630399","article-title":"Left bundle branch pacing: current knowledge and future prospects","volume":"8","author":"Liu","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1161\/CIRCULATIONAHA.120.052048","article-title":"Sodium-glucose cotransporter 2 inhibitors in patients with heart failure with reduced ejection fraction: the heart and kidney working better together","volume":"143","author":"Carnicelli","year":"2021","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1237118\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T19:23:59Z","timestamp":1692818639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1237118\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":24,"alternative-id":["10.3389\/fcvm.2023.1237118"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1237118","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"article-number":"1237118"}}